Alpha-1 antitrypsin - Omni Bio Pharmaceutical

Drug Profile

Alpha-1 antitrypsin - Omni Bio Pharmaceutical

Alternative Names: p-AAT; Plasma-derived alpha 1 antitrypsin - Omni Bio Pharmaceutical

Latest Information Update: 07 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Colorado at Denver
  • Developer Colorado State University; Omni Bio Pharmaceutical; University of Colorado at Denver; Virginia Commonwealth University
  • Class Acute-phase proteins; Alpha globulins; Blood proteins; Secretory proteinase inhibitory proteins; Serpins
  • Mechanism of Action Pancreatic elastase inhibitors; Trypsin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Anthrax; Graft-versus-host disease; HIV infections; Influenza virus infections; Myocardial infarction; Pneumonia; Tuberculosis; Type 1 diabetes mellitus; Type 2 diabetes mellitus

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 09 Dec 2014 Interim efficacy, adverse events and pharmacodynamics data from a phase I/II trial in Graft-versus-host disease presented at the 56th Annual Meeting and Exposition of the American Society of Hematology (ASH-2014)
  • 30 Apr 2014 Final efficacy, adverse events and pharmacodynamics data from a clinical trial in Type 1 diabetes mellitus released by Omni Bio Pharmaceutical
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top